

RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco, California, 94080

June 27, 2022

Via EDGAR

Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Joshua Gorsky

Re: **RAPT Therapeutics, Inc.**
Registration Statement on Form S-3 Filed June 24, 2022
File No. 333-265812

To whom it may concern:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, RAPT Therapeutics, Inc. (the “**Company**”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-265812) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on June 29, 2022 or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to Courtney M.W. Tygesson of Cooley LLP at (312) 881-6500 and that such effectiveness also be confirmed in writing.

Very truly yours,

RAPT Therapeutics, Inc.

By: /s/ Rodney Young
Rodney Young
Chief Financial Officer

cc: Courtney M.W. Tygesson, Cooley LLP